Arthritis Rheumatol: Biologics can prevent cardiovascular events in rheumatoid arthritis

The study aims to assess whether bio-disease-improved anti-rheumatic anti-rheumatic drugs (bDMARDs) can reduce the risk of cardiovascular disease (CVD) in rheumatoid arthritis and whether there are potential benefits from affecting the formation or progression of coronary plaquesin this single-center, observational cohort study, 150 patients received computer tomography to assess coronary atherosclerosis (all, non-calcification, mixing/calcification, and low decay plaques)101 patients were evaluated repeatedly over a 6.9-to-0.3-year year to assess plaque progressionAll CVD events were documented in the forward-looking, including cardiac death, myocardial infarction, unstable angina, blood reconstruction, stroke, lameness, and hospitalization for heart failureUse the Framingham score to assess cardiovascular riskSection narrow score assesses the plaque burdenadjusted segment narrow scores, Framingham scores, and DAS28-CRP over time using edge structure models, it was found that the current use of bDMARD was associated with long-term CVD risk reduction (OR?0.15?95%CI?0.04-0.60)The presence of non-calcification and low attenuation plaques regulated the effect of bDMARDs on CVD risk; specifically, the use of bDMARD was associated with a reduction in CVD risk in patients with non-calcification or low attenuation plaques at baseline (OR?0.21,95% CI?0.04-0.99) and OR-0.08,0.01-0.70, respectively, rather than those without plaquesThe analysis of plaque progression by segment showed that bDMARD was converted into mixed/calcification plaques using bDMARD (OR?4.00 (95% CI? 1.05-15.32) )In patients without mixed/calcification plaques in other coronary segments, bDMARD was used to predict the lower likelihood of new plaque formation in the plaque-free segment (OR?0.40(95% CI?0.17-0.93) but not in calcification patientsThe bDMARD treatment also predicted a reduction in low decay plaques (p-0.042)in rheumatoid arthritis, patients with early atherosclerosis were associated with a reduced risk of bDMARD, protective calcification of non-calcification lesions, and reduced likelihood of new plaque formation